Skip to main content

Dr. Daniel M. Geynisman, M.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
20
In the NPI registry since
2007
Medicare patients seen, 2024
235

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Medical school: University of Pittsburgh School of Medicine
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    PA license MD436806
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
235
Services billed
663
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes399195
Established patient office or other outpatient visit, 40-54 minutes210108
Established patient office or other outpatient visit, 20-29 minutes2825
New patient office or other outpatient visit, 60-74 minutes2222
New patient office or other outpatient visit, 45-59 minutes2020

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Abiraterone Acetate347
Prednisone
Other prescribers in Philadelphia, PA
335
Xtandi (enzalutamide)184
Orgovyx (relugolix)143
Nubeqa (darolutamide)107
Inlyta (axitinib)53
Cabometyx (cabozantinib s-malate)41
Erleada (apalutamide)39
Oxycodone Hcl
Other prescribers in Philadelphia, PA
32
Amlodipine Besylate
Other prescribers in Philadelphia, PA
32

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 34 payments worth $17,516 in total to this clinician.

By company
Exelixis Inc.$13,613
Avyxa Pharma, LLC$3,426
Pfizer Inc.$116
Taiho Oncology, Inc.$75.38
Daiichi Sankyo Inc.$68.46
AstraZeneca Pharmaceuticals LP$65.70
Gilead Sciences, Inc.$37.78
Merck Sharp & Dohme LLC$27.71
By type
Consulting Fee$11,220
Compensation for services other than consulting (speaking, faculty)$2,000
Honoraria$1,980
Travel and Lodging$1,338
Food and Beverage$936
Speaking at a medical education program$41.66

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 4, 2025Exelixis Inc.
Sep 4, 2025
Consulting Fee
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$7,920
Nov 13, 2025Exelixis Inc.
Nov 13, 2025
Consulting Fee
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,300
Sep 13, 2025Avyxa Pharma, LLC
Sep 13, 2025
Compensation for services other than consulting (speaking, faculty)$2,000
Nov 20, 2025Exelixis Inc.
Nov 20, 2025
Honoraria
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Sep 13, 2025Avyxa Pharma, LLC
Sep 13, 2025
Travel and Lodging
travel to MIAMI BEACH, FL · in-kind
$648
Sep 13, 2025Avyxa Pharma, LLC
Sep 13, 2025
Travel and Lodging
travel to MIAMI BEACH, FL · in-kind
$591
Jan 22, 2025Taiho Oncology, Inc.
Jan 22, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$35.91
Apr 30, 2025Taiho Oncology, Inc.
Apr 30, 2025
Speaking at a medical education program$24.80
Jan 22, 2025AstraZeneca Pharmaceuticals LP
Jan 22, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$24.42
Jan 22, 2025AstraZeneca Pharmaceuticals LP
Jan 22, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$24.42
All 12 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Nov 20, 2025Exelixis Inc.
Nov 20, 2025
Honoraria
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Nov 13, 2025Exelixis Inc.
Nov 13, 2025
Consulting Fee
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,300
Sep 13, 2025Avyxa Pharma, LLC
Sep 13, 2025
Compensation for services other than consulting (speaking, faculty)$2,000
Sep 13, 2025Avyxa Pharma, LLC
Sep 13, 2025
Travel and Lodging
travel to MIAMI BEACH, FL · in-kind
$648
Sep 13, 2025Avyxa Pharma, LLC
Sep 13, 2025
Travel and Lodging
travel to MIAMI BEACH, FL · in-kind
$591
Sep 4, 2025Exelixis Inc.
Sep 4, 2025
Consulting Fee
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$7,920
Apr 30, 2025Taiho Oncology, Inc.
Apr 30, 2025
Speaking at a medical education program$24.80
Apr 30, 2025AstraZeneca Pharmaceuticals LP
Apr 30, 2025
Speaking at a medical education program$16.86
Apr 30, 2025Taiho Oncology, Inc.
Apr 30, 2025
Travel and Lodging
travel to Orlando, FL
$14.67
Jan 22, 2025Taiho Oncology, Inc.
Jan 22, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$35.91
Jan 22, 2025AstraZeneca Pharmaceuticals LP
Jan 22, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$24.42
Jan 22, 2025AstraZeneca Pharmaceuticals LP
Jan 22, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$24.42

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $841,899 in research payments for these studies, mostly to the institutions running them.

  • A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
    Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05125016
  • A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Pa…
    Novartis Pharmaceuticals Corporation
  • An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
    Astellas Pharma Global Development
  • A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced,Metastatic Non-clear Cell Renal Cell Carcinoma nccRCC KEYNOTE-B61
    Merck Sharp & Dohme LLC
  • A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
    Amgen Inc.
  • A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
    Pfizer Inc.
  • A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Novartis Pharmaceuticals Corporation
  • A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIB…
    Merck Sharp & Dohme LLC
  • A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
    AstraZeneca UK Limited

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Philadelphia

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 9, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1437343597. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.